Lesson
Connect Environmental Exposure to Immune Failure
MAC is common in the environment but disseminated disease is uncommon when cellular immunity and HIV control are intact. The clinical problem is host failure, not ordinary contact with another person.
- Environmental NTM
- CD4 below 50
- HIV viremia
- Dissemination
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Place the organism
Mycobacterium avium complex includes environmental nontuberculous mycobacteria acquired through repeated inhalation or ingestion. Food, water, soil, and aerosols can contain the organism, while person-to-person transmission is unlikely.
Define the immune threshold
Disseminated disease occurs most often when the CD4 count is below 50 cells/mm3. Ongoing HIV replication, prior opportunistic infections, and absent immune recovery increase risk beyond the CD4 value alone.
Follow the path
Organisms entering through respiratory or gastrointestinal mucosa can reach the bloodstream and reticuloendothelial organs when macrophage control fails. Blood, liver, spleen, lymph nodes, marrow, and the GI tract may be involved.
Recognize the ART effect
Effective ART has reduced MAC incidence dramatically. Viral suppression is the dominant preventive intervention because it restores pathogen-specific immunity and reduces additional opportunistic disease.
Quick check
Lesson
Recognize the Syndrome and Prove the Organism
Disseminated MAC often begins with nonspecific systemic illness. Confirmation requires compatible disease plus recovery of MAC from blood or another normally sterile site.
- Fever
- Anemia
- Alkaline phosphatase
- Blood culture
- Resistance testing
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Read the systemic pattern
Fever, night sweats, weight loss, fatigue, diarrhea, and abdominal pain may appear weeks before culture confirmation. Hepatomegaly, splenomegaly, and deep lymphadenopathy can reveal multiorgan disease.
Use laboratory clues
Anemia that is greater than expected for the stage of HIV and elevated alkaline phosphatase are classic signals. They increase suspicion but do not establish the diagnosis.
Confirm from a sterile site
Obtain mycobacterial blood cultures and sample lymph fluid, marrow, or another sterile site when the presentation requires it. Blood culture is often more useful than marrow culture when bacteremia is present.
Separate colonization
Respiratory or GI isolation without compatible disease may represent colonization. Routine screening and preemptive treatment of asymptomatic colonization are not recommended.
Define the isolate
Positive cultures should undergo species identification and phenotypic macrolide susceptibility testing. Molecular assays can supplement this work by detecting rrl, rrs, or erm-associated resistance changes.
Quick check
Lesson
Use the Modern Prophylaxis Gate
Primary prophylaxis is no longer automatic for every CD4 count below 50. Immediate suppressive ART usually replaces it.
- CD4 below 50
- Viremia
- Azithromycin
- Clarithromycin
- Rifabutin
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Apply the full indication
Use prophylaxis when CD4 is below 50 cells/mm3 and the person is not receiving ART, remains viremic on ART, or has no fully suppressive ART option. Do not add prophylaxis when effective ART begins immediately.
Exclude active disease first
Review systemic symptoms and obtain a blood culture when appropriate. If a culture is obtained, wait for the result before starting prophylactic monotherapy so occult disease is not exposed to one active drug.
Choose a preferred macrolide
Options are azithromycin 1,200 mg once weekly, clarithromycin 500 mg twice daily, or azithromycin 600 mg twice weekly. Selection depends on adherence, interactions, tolerance, pregnancy, and cardiac and hepatic context.
Reserve rifabutin
Rifabutin 300 mg daily is an alternative when macrolides cannot be used. Exclude active tuberculosis and reconcile ART interactions before the first dose.
Stop when suppression succeeds
Previously started primary prophylaxis should stop once a fully suppressive ART regimen is established. Continuing it adds pill burden, toxicity, interactions, and resistance pressure without established additional benefit.
Quick check
Lesson
Protect the Macrolide Backbone
A macrolide kills susceptible MAC while ethambutol lowers relapse and resistance risk. Their roles are complementary and neither should be treated as optional convenience therapy.
- Clarithromycin
- Azithromycin
- Ethambutol
- Optic neuropathy
- Macrolide resistance
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Use clarithromycin deliberately
Clarithromycin 500 mg twice daily has extensive treatment evidence. Do not exceed 1 g per day because higher doses were associated with increased mortality. Metallic taste, GI effects, hepatic injury, QT risk, and CYP interactions require review.
Use azithromycin for a cleaner interaction fit
Azithromycin 500 to 600 mg daily has comparable efficacy and avoids CYP metabolism. It is useful when clarithromycin interactions, intolerance, or twice-daily adherence are problematic, but QT, liver, and GI risks still matter.
Dose ethambutol by weight
Ethambutol 15 mg/kg daily is the recommended companion. Adjust for renal impairment and document the weight used for dosing.
Protect vision
Establish visual acuity and color discrimination, then teach urgent reporting of blurred vision, central scotoma, or color change. Renal accumulation, higher exposure, and long duration heighten concern.
Test susceptibility
Macrolide susceptibility is central to regimen integrity, especially after breakthrough during prophylaxis. A resistant macrolide cannot anchor the regimen simply because it remains familiar.
Quick check
Lesson
Scale Initial Therapy to Disease Burden
At least two active drugs are required. Additional agents belong to severe, high-burden, unsuppressed, or resistance-prone disease rather than routine uncomplicated treatment.
- Two-drug backbone
- Rifabutin
- High burden
- Fluoroquinolones
- Salvage therapy
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Build the minimum regimen
Use clarithromycin 500 mg twice daily plus ethambutol 15 mg/kg daily, or azithromycin 500 to 600 mg daily plus ethambutol. Confirm susceptibility and individualize for organ function and interactions.
Recognize intensification triggers
Consider a third or fourth drug with severe disease, high mortality risk, blood burden above 2 log10 CFU/mL, prophylaxis failure, absent ART, or lack of viral suppression.
Add rifabutin third
Rifabutin 300 mg daily is the usual third drug. Its dose may change with ART, and some combinations are contraindicated or impractical.
Use fourth agents cautiously
Levofloxacin 500 mg daily or moxifloxacin 400 mg daily can be considered. Amikacin 10 to 15 mg/kg IV daily should generally be reserved for refractory disease when safer alternatives are unavailable and drug-level monitoring is possible.
Frame salvage evidence honestly
Bedaquiline, linezolid, tedizolid, omadacycline, and selected dual beta-lactams show in vitro activity. They are specialist-directed refractory options, not interchangeable first-line agents.
Quick check
Lesson
Start ART and Engineer the Interaction Plan
Immune restoration and antimycobacterial therapy should proceed together. Interaction management should modify the regimen, not delay effective ART without reason.
- Concurrent ART
- CYP3A4
- Boosters
- Rifabutin
- Virologic suppression
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Begin ART promptly
A person not receiving effective ART should start as soon as possible, preferably when MAC therapy begins. Continue existing ART and modify incompatible drugs rather than stopping immune restoration.
Map clarithromycin exposure
Boosted protease inhibitors and elvitegravir/cobicistat can increase clarithromycin concentrations. Dose adjustment or substitution with azithromycin may reduce toxicity and complexity.
Map rifabutin in both directions
Rifabutin is a CYP3A4 inducer and substrate. Boosters can raise rifabutin exposure, efavirenz can lower it, and rifabutin can reduce exposure to selected ARVs.
Recognize high-stakes combinations
Do not combine rifabutin with cobicistat-boosted protease inhibitors, elvitegravir/cobicistat, long-acting cabotegravir/rilpivirine, or lenacapavir without current specialist guidance. Loss of ARV exposure can cause virologic failure and resistance.
Monitor the person, not only the table
Track HIV RNA, CD4, MAC response, CBC, liver tests, ocular symptoms, adherence, and tolerability. Therapeutic drug monitoring can help in unusually complex interactions.
Quick check
Lesson
Let Response and Immune Recovery Set the Endpoint
Symptoms often improve within weeks, but cure requires sustained antimicrobial exposure and restored host control. One calendar date cannot decide completion.
- 2 to 4 weeks
- Treatment failure
- 12 months
- CD4 above 100
- Maintenance
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Expect an early trajectory
Fever and systemic symptoms often improve within 2 to 4 weeks. Extensive disease and profound immunosuppression can delay response.
Define failure precisely
Absent clinical response with persistent mycobacteremia or positive tissue cultures after 4 to 8 weeks meets the treatment-failure frame. Recheck adherence, interactions, absorption, diagnosis, and susceptibility.
Rebuild a failing regimen
Repeat susceptibility testing after relapse or failure. Construct a new multidrug regimen with at least two previously unused agents to which the isolate is susceptible rather than adding one drug to a failing backbone.
Meet every stopping criterion
Treat for at least 12 months, resolve signs and symptoms, and sustain CD4 above 100 cells/mm3 for at least 6 months in response to ART before stopping maintenance.
Restart for lost host control
Restart chronic maintenance when fully suppressive ART is not possible and CD4 remains below 100. A transient isolated CD4 dip during suppression is not the same situation.
Quick check
Lesson
Separate MAC IRIS from Treatment Failure
Immune recovery can reveal occult MAC or intensify inflammation around known disease. The pattern can resemble active infection, so microbiology and regimen evidence matter.
- Unmasking IRIS
- Paradoxical IRIS
- NSAIDs
- Prednisone
- Continue ART
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Name the two patterns
Unmasking IRIS reveals previously undiagnosed MAC after ART begins. Paradoxical IRIS worsens known disease after MAC treatment or ART starts.
Recognize the clinical overlap
Fever, fatigue, lymphadenopathy, abdominal pain, diarrhea, and weight loss can resemble active disseminated disease. Bacteremia is usually absent in IRIS except during unmasking disease.
Do not skip the failure check
Review adherence, drug exposure, interactions, susceptibility, cultures, and new organ involvement before attributing severe progression entirely to inflammation.
Treat inflammation by severity
Continue effective ART and MAC therapy. Use NSAIDs for mild or moderate symptoms. For severe unremitting IRIS, consider prednisone 20 to 40 mg daily for 4 to 8 weeks after evaluating infection and steroid risks.
Escalate organ-threatening disease
Severe or persistent IRIS, including hemophagocytic syndromes, requires specialist management and may need prolonged anti-inflammatory therapy.
Quick check
Lesson
Use Current Pregnancy Evidence
Pregnancy decisions rely on present benefit and safety evidence, disease severity, and effective ART, not obsolete pregnancy-letter categories.
- Pregnancy
- Azithromycin
- Ethambutol
- Rifabutin
- Shared management
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Prevent with ART first
When effective ART begins immediately, primary MAC prophylaxis is not recommended during pregnancy. If prophylaxis remains necessary because suppressive ART is unavailable, azithromycin is preferred.
Avoid clarithromycin first line
Clarithromycin is not a first-line prophylaxis or treatment choice during pregnancy. This is a pregnancy-specific evidence judgment rather than an old letter-category rule.
Build treatment around azithromycin and ethambutol
Azithromycin plus ethambutol is the preferred maintenance combination during pregnancy. Add rifabutin when severe disease requires a third agent after interaction review.
Coordinate monitoring
HIV, infectious disease, obstetric, and pharmacy teams should coordinate ART, antimicrobial exposure, vision, CBC, liver tests, symptoms, and adherence.
Quick check
Lesson
Close Every Loop in Disseminated MAC Care
A technically correct prescription can still fail if cultures, resistance results, ART delivery, interactions, toxicity, or follow-up have no owner.
- Culture ownership
- Medication access
- ART suppression
- Toxicity surveillance
- Transition plan
Carry this evidence forward.
Carry this evidence forward.
Carry this evidence forward.
Own the next clinical action.
Own the diagnostic result
Track blood and tissue cultures through species identification and susceptibility. Communicate every result to the team that can change therapy.
Own medication delivery
Confirm the full MAC and ART regimens are available together. Reconcile refill dates, swallowing barriers, intolerance, and every prescription and nonprescription interaction.
Own the monitoring
Schedule symptom, weight, CBC, liver, renal, visual, HIV RNA, CD4, and culture follow-up according to the regimen and response. A missed result should trigger action rather than disappear.
Own the endpoint
Document the treatment start, response, minimum duration, sustained CD4 recovery, viral suppression, maintenance decision, and restart conditions.
Teach actionable warnings
Explain which symptoms are expected, which suggest optic toxicity, uveitis, marrow or liver injury, arrhythmia, treatment failure, or IRIS, and exactly who to contact.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 136 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.